Literature DB >> 17067278

Flying under the radar: the immunobiology of hepatitis C.

Lynn B Dustin1, Charles M Rice.   

Abstract

The hepatitis C virus (HCV) is a remarkably successful pathogen, establishing persistent infection in more than two-thirds of those who contract it. Its success is related to its abilities to blunt innate antiviral pathways and to evade adaptive immune responses. These two themes may be related. We propose that HCV takes advantage of the impaired innate response to delay the organization of an effective adaptive immune attack. The tolerogenic liver environment may provide cover, prolonging this delay. HCV's error-prone replication strategy permits rapid evolution under immune pressure. Persistent high levels of viral antigens may contribute to immune exhaustion. Finally, the virus may benefit from the efficient enlistment of memory T and B cells in the pursuit of a moving target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17067278     DOI: 10.1146/annurev.immunol.25.022106.141602

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  125 in total

1.  A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

Authors:  Michael C Sneller; Zonghui Hu; Carol A Langford
Journal:  Arthritis Rheum       Date:  2012-03

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 3.  The interferon inducible gene: Viperin.

Authors:  Katherine A Fitzgerald
Journal:  J Interferon Cytokine Res       Date:  2010-12-12       Impact factor: 2.607

4.  Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species.

Authors:  Robert S Tacke; Hai-Chon Lee; Celeste Goh; Jeremy Courtney; Stephen J Polyak; Hugo R Rosen; Young S Hahn
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

5.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

Review 6.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

7.  Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.

Authors:  Robert S Tacke; Annie Tosello-Trampont; Virginia Nguyen; David W Mullins; Young S Hahn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 8.  Chemokines in the immunopathogenesis of hepatitis C infection.

Authors:  Mathis Heydtmann; David H Adams
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 9.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

10.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.